United States of America

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National

Download

Value (%)	Year	Type	Source
0.34 (0.30 - 0.38)	2019	Modelled	IHME
0.34 (0.30 - 0.38)	2018	Modelled	IHME
0.34 (0.30 - 0.39)	2017	Modelled	IHME
0.35 (0.31 - 0.39)	2016	Modelled	IHME
0.36 (0.32 - 0.41)	2015	Modelled	IHME
0.37 (0.33 - 0.42)	2014	Modelled	IHME
0.38 (0.33 - 0.42)	2013	Modelled	IHME
0.38 (0.34 - 0.43)	2012	Modelled	IHME
0.39 (0.34 - 0.44)	2011	Modelled	IHME
0.4 (0.35 - 0.45)	2010	Modelled	IHME
0.41 (0.36 - 0.46)	2009	Modelled	IHME
0.42 (0.37 - 0.47)	2008	Modelled	IHME
0.43 (0.37 - 0.48)	2007	Modelled	IHME
0.44 (0.38 - 0.49)	2006	Modelled	IHME
0.44 (0.39 - 0.50)	2005	Modelled	IHME
0.45 (0.39 - 0.51)	2004	Modelled	IHME
0.45 (0.40 - 0.51)	2003	Modelled	IHME
0.46 (0.40 - 0.52)	2002	Modelled	IHME
0.46 (0.40 - 0.52)	2001	Modelled	IHME
0.47 (0.41 - 0.52)	2000	Modelled	IHME
0.47 (0.41 - 0.53)	1999	Modelled	IHME
0.48 (0.42 - 0.54)	1998	Modelled	IHME
0.49 (0.42 - 0.55)	1997	Modelled	IHME
0.49 (0.43 - 0.56)	1996	Modelled	IHME
0.5 (0.43 - 0.56)	1995	Modelled	IHME
0.5 (0.44 - 0.57)	1994	Modelled	IHME
0.51 (0.44 - 0.58)	1993	Modelled	IHME
0.51 (0.45 - 0.58)	1992	Modelled	IHME
0.52 (0.45 - 0.59)	1991	Modelled	IHME
0.52 (0.45 - 0.59)	1990	Modelled	IHME
0.38 (0.29 - 0.49)	1994	Survey/reported	Wasley A et al, 2010
0.27 (0.20 - 0.35)	2006	Survey/reported	Wasley A et al, 2010
0.3 (0.20 - 0.40)	2012	Survey/reported	Roberts H et al, 2016
0.23 (0.18 - 0.28)	2015	Modelled	WHO
0.3 (0.20 - 0.30)	2016	Modelled	Razavi-Shearer et al, 2018
0.27 (0.24 - 0.30)	2013	Modelled	Schweitzer et al, 2015

Showing out of

Children under-5 years

Download

Value (%)	Year	Type	Source
0.03 (0.02 - 0.04)	2019	Modelled	IHME
0.03 (0.02 - 0.04)	2018	Modelled	IHME
0.03 (0.02 - 0.04)	2017	Modelled	IHME
0.03 (0.02 - 0.04)	2016	Modelled	IHME
0.03 (0.02 - 0.04)	2015	Modelled	IHME
0.03 (0.02 - 0.04)	2014	Modelled	IHME
0.03 (0.03 - 0.04)	2013	Modelled	IHME
0.03 (0.03 - 0.04)	2012	Modelled	IHME
0.04 (0.03 - 0.04)	2011	Modelled	IHME
0.04 (0.03 - 0.04)	2010	Modelled	IHME
0.03 (0.03 - 0.04)	2009	Modelled	IHME
0.03 (0.03 - 0.04)	2008	Modelled	IHME
0.03 (0.02 - 0.04)	2007	Modelled	IHME
0.03 (0.02 - 0.04)	2006	Modelled	IHME
0.03 (0.02 - 0.04)	2005	Modelled	IHME
0.03 (0.02 - 0.04)	2004	Modelled	IHME
0.03 (0.02 - 0.04)	2003	Modelled	IHME
0.03 (0.03 - 0.04)	2002	Modelled	IHME
0.04 (0.03 - 0.05)	2001	Modelled	IHME
0.04 (0.03 - 0.05)	2000	Modelled	IHME
0.04 (0.03 - 0.05)	1999	Modelled	IHME
0.04 (0.03 - 0.05)	1998	Modelled	IHME
0.04 (0.03 - 0.06)	1997	Modelled	IHME
0.05 (0.04 - 0.06)	1996	Modelled	IHME
0.05 (0.04 - 0.07)	1995	Modelled	IHME
0.06 (0.04 - 0.08)	1994	Modelled	IHME
0.07 (0.05 - 0.09)	1993	Modelled	IHME
0.09 (0.07 - 0.11)	1992	Modelled	IHME
0.11 (0.08 - 0.13)	1991	Modelled	IHME
0.13 (0.10 - 0.16)	1990	Modelled	IHME
0.04 (0.03 - 0.05)	2015	Modelled	WHO

Showing out of

Technical notes

Number of people living with chronic HBV

National

Download

Value	Year	Type	Source
1,317,810 (1,141,740 - 1,502,300)	1990	Modelled	IHME
1,324,240 (1,147,580 - 1,507,310)	1991	Modelled	IHME
1,329,060 (1,153,480 - 1,508,030)	1992	Modelled	IHME
1,332,170 (1,156,540 - 1,512,760)	1993	Modelled	IHME
1,333,670 (1,159,600 - 1,507,970)	1994	Modelled	IHME
1,333,900 (1,159,670 - 1,504,050)	1995	Modelled	IHME
1,331,460 (1,158,810 - 1,498,340)	1996	Modelled	IHME
1,326,130 (1,153,930 - 1,494,180)	1997	Modelled	IHME
1,319,570 (1,149,530 - 1,484,540)	1998	Modelled	IHME
1,313,590 (1,146,460 - 1,476,340)	1999	Modelled	IHME
1,310,100 (1,142,500 - 1,472,620)	2000	Modelled	IHME
1,309,770 (1,143,240 - 1,473,390)	2001	Modelled	IHME
1,311,250 (1,143,560 - 1,474,490)	2002	Modelled	IHME
1,313,140 (1,147,220 - 1,476,360)	2003	Modelled	IHME
1,313,740 (1,147,160 - 1,476,070)	2004	Modelled	IHME
1,311,240 (1,142,650 - 1,473,160)	2005	Modelled	IHME
1,302,020 (1,136,430 - 1,465,600)	2006	Modelled	IHME
1,285,820 (1,126,040 - 1,446,130)	2007	Modelled	IHME
1,265,750 (1,112,440 - 1,424,060)	2008	Modelled	IHME
1,245,300 (1,096,350 - 1,399,520)	2009	Modelled	IHME
1,228,380 (1,079,050 - 1,381,060)	2010	Modelled	IHME
1,216,570 (1,069,660 - 1,365,180)	2011	Modelled	IHME
1,207,220 (1,061,900 - 1,352,310)	2012	Modelled	IHME
1,197,990 (1,053,860 - 1,340,010)	2013	Modelled	IHME
1,186,460 (1,041,800 - 1,328,430)	2014	Modelled	IHME
1,169,910 (1,025,460 - 1,309,720)	2015	Modelled	IHME
1,136,010 (994,511 - 1,273,420)	2016	Modelled	IHME
1,109,810 (970,219 - 1,253,650)	2017	Modelled	IHME
1,106,910 (968,416 - 1,250,170)	2018	Modelled	IHME
1,108,930 (968,729 - 1,253,410)	2019	Modelled	IHME
875,000 (654,000 - 1,033,000)	2016	Modelled	Razavi-Shearer et al, 2018

Showing out of

HBV-related death rate

National

Download

Value (per 100,000)	Year	Type	Source
1.37 (1.18 - 1.58)	2019	Modelled	IHME
1.36 (1.18 - 1.55)	2018	Modelled	IHME
1.34 (1.17 - 1.52)	2017	Modelled	IHME
1.4 (1.25 - 1.57)	2016	Modelled	IHME
1.43 (1.28 - 1.59)	2015	Modelled	IHME
1.39 (1.25 - 1.54)	2014	Modelled	IHME
1.35 (1.22 - 1.50)	2013	Modelled	IHME
1.31 (1.18 - 1.45)	2012	Modelled	IHME
1.27 (1.15 - 1.40)	2011	Modelled	IHME
1.24 (1.12 - 1.36)	2010	Modelled	IHME
1.22 (1.11 - 1.34)	2009	Modelled	IHME
1.2 (1.10 - 1.32)	2008	Modelled	IHME
1.19 (1.08 - 1.29)	2007	Modelled	IHME
1.18 (1.08 - 1.28)	2006	Modelled	IHME
1.16 (1.06 - 1.26)	2005	Modelled	IHME
1.13 (1.03 - 1.23)	2004	Modelled	IHME
1.13 (1.03 - 1.23)	2003	Modelled	IHME
1.12 (1.02 - 1.22)	2002	Modelled	IHME
1.1 (1.01 - 1.20)	2001	Modelled	IHME
1.08 (0.99 - 1.18)	2000	Modelled	IHME
1.06 (0.97 - 1.15)	1999	Modelled	IHME
1.03 (0.95 - 1.12)	1998	Modelled	IHME
1.01 (0.93 - 1.10)	1997	Modelled	IHME
1 (0.91 - 1.08)	1996	Modelled	IHME
0.99 (0.90 - 1.07)	1995	Modelled	IHME
0.97 (0.89 - 1.06)	1994	Modelled	IHME
0.97 (0.88 - 1.06)	1993	Modelled	IHME
0.96 (0.86 - 1.05)	1992	Modelled	IHME
0.97 (0.87 - 1.06)	1991	Modelled	IHME
0.99 (0.88 - 1.10)	1990	Modelled	IHME
0.5	2014	Survey/reported	US CDC
0.45	2016	Survey/reported	US CDC
0.46	2017	Survey/reported	US CDC
0.52	2010	Survey/reported	US CDC
0.51	2011	Survey/reported	US CDC
0.51	2012	Survey/reported	US CDC
0.53	2013	Survey/reported	US CDC
0.46	2015	Survey/reported	US CDC

Showing out of

Technical notes

HBV-related deaths

National

Download

Value	Year	Type	Source
4,486 (3,874 - 5,178)	2019	Modelled	IHME
4,422 (3,862 - 5,064)	2018	Modelled	IHME
4,345 (3,813 - 4,935)	2017	Modelled	IHME
4,516 (4,023 - 5,073)	2016	Modelled	IHME
4,584 (4,107 - 5,100)	2015	Modelled	IHME
4,423 (3,984 - 4,917)	2014	Modelled	IHME
4,261 (3,856 - 4,728)	2013	Modelled	IHME
4,108 (3,718 - 4,543)	2012	Modelled	IHME
3,965 (3,595 - 4,371)	2011	Modelled	IHME
3,817 (3,459 - 4,201)	2010	Modelled	IHME
3,739 (3,397 - 4,099)	2009	Modelled	IHME
3,654 (3,327 - 4,001)	2008	Modelled	IHME
3,569 (3,252 - 3,893)	2007	Modelled	IHME
3,498 (3,202 - 3,815)	2006	Modelled	IHME
3,408 (3,118 - 3,714)	2005	Modelled	IHME
3,292 (3,017 - 3,587)	2004	Modelled	IHME
3,262 (2,985 - 3,558)	2003	Modelled	IHME
3,196 (2,930 - 3,479)	2002	Modelled	IHME
3,120 (2,858 - 3,393)	2001	Modelled	IHME
3,041 (2,791 - 3,302)	2000	Modelled	IHME
2,947 (2,705 - 3,193)	1999	Modelled	IHME
2,845 (2,611 - 3,087)	1998	Modelled	IHME
2,752 (2,520 - 2,989)	1997	Modelled	IHME
2,688 (2,461 - 2,917)	1996	Modelled	IHME
2,639 (2,413 - 2,869)	1995	Modelled	IHME
2,576 (2,351 - 2,803)	1994	Modelled	IHME
2,533 (2,299 - 2,770)	1993	Modelled	IHME
2,479 (2,241 - 2,724)	1992	Modelled	IHME
2,475 (2,228 - 2,727)	1991	Modelled	IHME
2,498 (2,240 - 2,778)	1990	Modelled	IHME
11,522	2016	Modelled	WHO

Showing out of

Technical notes

Percent of liver cancer deaths attributable to HBV

National

Download

Value (%)	Year	Type	Source
12 (10 - 14)	2019	Modelled	IHME
12 (10 - 14)	2018	Modelled	IHME
12 (10 - 14)	2017	Modelled	IHME
12 (10 - 14)	2016	Modelled	IHME
12 (10 - 14)	2015	Modelled	IHME
12 (11 - 14)	2014	Modelled	IHME
12 (11 - 14)	2013	Modelled	IHME
12 (11 - 14)	2012	Modelled	IHME
12 (11 - 14)	2011	Modelled	IHME
12 (11 - 14)	2010	Modelled	IHME
13 (11 - 14)	2009	Modelled	IHME
13 (11 - 14)	2008	Modelled	IHME
13 (11 - 14)	2007	Modelled	IHME
13 (11 - 15)	2006	Modelled	IHME
13 (11 - 15)	2005	Modelled	IHME
13 (12 - 15)	2004	Modelled	IHME
13 (12 - 15)	2003	Modelled	IHME
13 (12 - 15)	2002	Modelled	IHME
13 (12 - 15)	2001	Modelled	IHME
13 (12 - 15)	2000	Modelled	IHME
13 (12 - 14)	1999	Modelled	IHME
13 (11 - 14)	1998	Modelled	IHME
13 (11 - 14)	1997	Modelled	IHME
13 (11 - 14)	1996	Modelled	IHME
13 (11 - 14)	1995	Modelled	IHME
13 (11 - 14)	1994	Modelled	IHME
13 (11 - 14)	1993	Modelled	IHME
13 (11 - 15)	1992	Modelled	IHME
13 (11 - 15)	1991	Modelled	IHME
13 (11 - 15)	1990	Modelled	IHME

Showing out of

Technical notes

Coverage of HepB birth dose

Newborns

Download

Value (%)	Year	Type	Source
66	2018	Survey/reported	WHO/UNICEF
64	2017	Survey/reported	WHO/UNICEF
64	2016	Survey/reported	WHO/UNICEF
72	2015	Survey/reported	WHO/UNICEF
72	2014	Survey/reported	WHO/UNICEF
74	2013	Survey/reported	WHO/UNICEF
72	2012	Survey/reported	WHO/UNICEF
69	2011	Survey/reported	WHO/UNICEF
64	2010	Survey/reported	WHO/UNICEF
61	2009	Survey/reported	WHO/UNICEF
55	2008	Survey/reported	WHO/UNICEF
53	2007	Survey/reported	WHO/UNICEF
50	2006	Survey/reported	WHO/UNICEF
50	2005	Survey/reported	WHO/UNICEF
48	2004	Survey/reported	WHO/UNICEF
39	2003	Survey/reported	WHO/UNICEF
21	2002	Survey/reported	WHO/UNICEF
67	2019	Survey/reported	WHO/UNICEF

Showing out of

Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants

Download

Value (%)	Year	Type	Source
91	2018	Survey/reported	WHO/UNICEF
93	2017	Survey/reported	WHO/UNICEF
93	2016	Survey/reported	WHO/UNICEF
92	2015	Survey/reported	WHO/UNICEF
92	2014	Survey/reported	WHO/UNICEF
91	2013	Survey/reported	WHO/UNICEF
90	2012	Survey/reported	WHO/UNICEF
91	2011	Survey/reported	WHO/UNICEF
92	2010	Survey/reported	WHO/UNICEF
92	2009	Survey/reported	WHO/UNICEF
94	2008	Survey/reported	WHO/UNICEF
93	2007	Survey/reported	WHO/UNICEF
93	2006	Survey/reported	WHO/UNICEF
93	2005	Survey/reported	WHO/UNICEF
92	2004	Survey/reported	WHO/UNICEF
92	2003	Survey/reported	WHO/UNICEF
88	2002	Survey/reported	WHO/UNICEF
89	2001	Survey/reported	WHO/UNICEF
90	2000	Survey/reported	WHO/UNICEF
88	1999	Survey/reported	WHO/UNICEF
87	1998	Survey/reported	WHO/UNICEF
84	1997	Survey/reported	WHO/UNICEF
82	1996	Survey/reported	WHO/UNICEF
68	1995	Survey/reported	WHO/UNICEF
42	1994	Survey/reported	WHO/UNICEF
16	1993	Survey/reported	WHO/UNICEF
91	2019	Survey/reported	WHO/UNICEF

Showing out of

Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)

Download

Value	Year	Type	Source
30 (11 - 49)	2016	Survey/reported	NASEN, 2015; Wejnert C et al, 2016; Des Jarlais D et al , 2013

Technical notes

HBV National Action Plan

Source:

HBV elimination goal

Source:

HBV testing policy

Pregnant women, Risk-based

Source:

HepB birth dose policy

Yes

Source: WHO

Year of birth dose introduction

1999

Source: WHO

Eligible for HBV generic medicines

Source: MPP

HCV National Action Plan

Source:

HCV elimination goal

Source:

HCV testing policy

Universal

Source:

Eligible for HCV generic medicines

Source: MPP

At least one needle-syringe exchange program (NSP) operational

Yes

Source: Harm Reduction International

At least one opioid substitution therapy (OST) program operational

Yes

Source: Harm Reduction International

NSP in at least one prison

Source: Harm Reduction International

OST in at least one prison

Yes

Source: Harm Reduction International

% of substance use disorder facilities offering hepatitis testing

Many (31-60%)

Source: WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National

Download

Value (%)	Year	Type	Source
1.18 (0.95 - 1.45)	2019	Modelled	IHME
1.18 (0.96 - 1.45)	2018	Modelled	IHME
1.18 (0.96 - 1.45)	2017	Modelled	IHME
1.15 (0.94 - 1.41)	2016	Modelled	IHME
1.12 (0.91 - 1.38)	2015	Modelled	IHME
1.12 (0.91 - 1.37)	2014	Modelled	IHME
1.11 (0.90 - 1.36)	2013	Modelled	IHME
1.1 (0.90 - 1.36)	2012	Modelled	IHME
1.1 (0.89 - 1.36)	2011	Modelled	IHME
1.1 (0.89 - 1.36)	2010	Modelled	IHME
1.11 (0.90 - 1.37)	2009	Modelled	IHME
1.12 (0.90 - 1.38)	2008	Modelled	IHME
1.13 (0.91 - 1.40)	2007	Modelled	IHME
1.14 (0.92 - 1.41)	2006	Modelled	IHME
1.14 (0.92 - 1.42)	2005	Modelled	IHME
1.14 (0.92 - 1.42)	2004	Modelled	IHME
1.14 (0.92 - 1.41)	2003	Modelled	IHME
1.14 (0.92 - 1.41)	2002	Modelled	IHME
1.14 (0.92 - 1.41)	2001	Modelled	IHME
1.14 (0.92 - 1.41)	2000	Modelled	IHME
1.13 (0.91 - 1.40)	1999	Modelled	IHME
1.11 (0.89 - 1.38)	1998	Modelled	IHME
1.08 (0.87 - 1.34)	1997	Modelled	IHME
1.06 (0.85 - 1.31)	1996	Modelled	IHME
1.04 (0.83 - 1.29)	1995	Modelled	IHME
1.02 (0.82 - 1.27)	1994	Modelled	IHME
1.01 (0.81 - 1.26)	1993	Modelled	IHME
1 (0.81 - 1.25)	1992	Modelled	IHME
0.99 (0.80 - 1.24)	1991	Modelled	IHME
0.99 (0.79 - 1.23)	1990	Modelled	IHME
1 (0.80 - 1.10)	2016	Survey/reported	Hofmeister MG et al, 2019 (Adjusted)
1 (0.80 - 1.20)	2010	Survey/reported	Denniston MM et al, 2014 (Unadjusted)
1.3 (1 - 1.50)	2002	Survey/reported	Armstrong GL wt al, 2006 (Unadjusted)
0.9 (0.70 - 1.20)	2015	Modelled	Blach et al, 2017
0.84 (0.75 - 0.96)	2016	Survey/reported	Rosenberg et al, 2018 (Unadjusted)
0.93	2016	Survey/reported	Rosenberg et al, 2018 (Adjusted)
1 (0.90 - 1.80)	2014	Modelled	Gower et al, 2014

Showing out of

Technical notes

Prevalence of anti-HCV

National

Download

Value (%)	Year	Type	Source
1.7 (1.40 - 2)	2016	Survey/reported	Hofmeister MG et al, 2019 (Adjusted)
1.3 (1.20 - 1.50)	2010	Survey/reported	Denniston MM et al, 2014 (Unadjusted)
1.6 (1.30 - 1.90)	2002	Survey/reported	Armstrong GL wt al, 2006 (Unadjusted)
1.8 (1.50 - 2.30)	1994	Survey/reported	Alter MJ et al, 1999 (Unadjusted)
1.9 (1.50 - 2.50)	2002	Survey/reported	Ditah et al, 2014
1.3 (0.90 - 1.80)	2006	Survey/reported	Ditah et al, 2014
1.3 (1.20 - 2.40)	2014	Modelled	Gower et al, 2014
1.48	2019	Modelled	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis

Showing out of

Men who have sex with men (MSM)

Download

Value (%)	Year	Type	Source
4.4	2019	Modelled	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis

Men who have sex with men

Download

Value (%)	Year	Type	Source
9.7 (7.10 - 12.60)	2019	Modelled	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
53.1 (38.10 - 68)	2016	Modelled	Degenhardt L et al, 2017

Technical notes

Number of people living with chronic HCV (RNA+/cAg)

National

Download

Value	Year	Type	Source
2,502,880 (2,004,160 - 3,130,610)	1990	Modelled	IHME
2,546,430 (2,043,900 - 3,182,130)	1991	Modelled	IHME
2,596,220 (2,088,110 - 3,238,600)	1992	Modelled	IHME
2,650,820 (2,132,340 - 3,306,200)	1993	Modelled	IHME
2,709,170 (2,180,460 - 3,372,500)	1994	Modelled	IHME
2,770,670 (2,230,810 - 3,444,260)	1995	Modelled	IHME
2,848,100 (2,293,540 - 3,535,790)	1996	Modelled	IHME
2,945,160 (2,370,670 - 3,660,720)	1997	Modelled	IHME
3,046,070 (2,451,420 - 3,794,290)	1998	Modelled	IHME
3,134,450 (2,518,830 - 3,904,060)	1999	Modelled	IHME
3,193,420 (2,568,350 - 3,968,570)	2000	Modelled	IHME
3,230,980 (2,602,030 - 4,000,380)	2001	Modelled	IHME
3,267,410 (2,634,270 - 4,038,940)	2002	Modelled	IHME
3,303,160 (2,665,360 - 4,086,760)	2003	Modelled	IHME
3,338,110 (2,695,040 - 4,137,130)	2004	Modelled	IHME
3,372,040 (2,724,350 - 4,187,150)	2005	Modelled	IHME
3,392,560 (2,742,490 - 4,212,400)	2006	Modelled	IHME
3,394,700 (2,747,430 - 4,209,860)	2007	Modelled	IHME
3,389,100 (2,745,630 - 4,198,660)	2008	Modelled	IHME
3,387,400 (2,747,660 - 4,185,320)	2009	Modelled	IHME
3,402,520 (2,765,160 - 4,193,890)	2010	Modelled	IHME
3,432,790 (2,786,310 - 4,230,320)	2011	Modelled	IHME
3,467,850 (2,815,500 - 4,270,910)	2012	Modelled	IHME
3,507,740 (2,849,370 - 4,315,400)	2013	Modelled	IHME
3,552,530 (2,888,320 - 4,365,520)	2014	Modelled	IHME
3,601,660 (2,913,580 - 4,419,880)	2015	Modelled	IHME
3,722,760 (3,022,960 - 4,564,600)	2016	Modelled	IHME
3,829,820 (3,111,390 - 4,697,660)	2017	Modelled	IHME
3,850,280 (3,123,950 - 4,718,760)	2018	Modelled	IHME
3,865,100 (3,131,620 - 4,746,640)	2019	Modelled	IHME
2,936,000 (2,231,000 - 3,826,000)	2015	Modelled	Blach et al, 2017

Showing out of

HCV-related death rate

National

Download

Value (per 100,000)	Year	Type	Source
11.9 (10.80 - 13.10)	2019	Modelled	IHME
11.8 (10.70 - 13.10)	2018	Modelled	IHME
11.7 (10.60 - 12.90)	2017	Modelled	IHME
11.73 (10.80 - 12.80)	2016	Modelled	IHME
11.4 (10.60 - 12.40)	2015	Modelled	IHME
11.1 (10.30 - 12.10)	2014	Modelled	IHME
10.9 (10.10 - 11.80)	2013	Modelled	IHME
10.7 (9.88 - 11.50)	2012	Modelled	IHME
10.4 (9.69 - 11.20)	2011	Modelled	IHME
10.1 (9.40 - 10.90)	2010	Modelled	IHME
9.99 (9.28 - 10.80)	2009	Modelled	IHME
9.77 (9.09 - 10.50)	2008	Modelled	IHME
9.54 (8.88 - 10.30)	2007	Modelled	IHME
9.4 (8.76 - 10.10)	2006	Modelled	IHME
9.24 (8.62 - 9.95)	2005	Modelled	IHME
9.01 (8.41 - 9.68)	2004	Modelled	IHME
9 (8.41 - 9.66)	2003	Modelled	IHME
8.84 (8.27 - 9.48)	2002	Modelled	IHME
8.62 (8.08 - 9.25)	2001	Modelled	IHME
8.4 (7.87 - 9.01)	2000	Modelled	IHME
8.17 (7.63 - 8.78)	1999	Modelled	IHME
7.94 (7.39 - 8.53)	1998	Modelled	IHME
7.75 (7.23 - 8.33)	1997	Modelled	IHME
7.63 (7.10 - 8.20)	1996	Modelled	IHME
7.56 (7.03 - 8.13)	1995	Modelled	IHME
7.4 (6.87 - 7.95)	1994	Modelled	IHME
7.23 (6.70 - 7.80)	1993	Modelled	IHME
6.95 (6.41 - 7.53)	1992	Modelled	IHME
6.8 (6.24 - 7.43)	1991	Modelled	IHME
6.68 (6.07 - 7.37)	1990	Modelled	IHME
4.45	2016	Survey/reported	US CDC, 2016
4.91	2015	Survey/reported	US CDC, 2020
5.01	2014	Survey/reported	US CDC, 2019
5.03	2013	Survey/reported	US CDC, 2018
4.96	2012	Survey/reported	US CDC, 2017

Showing out of

Technical notes

HCV-related deaths

National

Download

Value	Year	Type	Source
39,158 (35,520 - 43,124)	2019	Modelled	IHME
38,668 (35,028 - 42,654)	2018	Modelled	IHME
38,054 (34,421 - 41,900)	2017	Modelled	IHME
37,842 (34,759 - 41,187)	2016	Modelled	IHME
36,565 (33,841 - 39,660)	2015	Modelled	IHME
35,460 (32,872 - 38,434)	2014	Modelled	IHME
34,425 (31,893 - 37,241)	2013	Modelled	IHME
33,475 (31,022 - 36,115)	2012	Modelled	IHME
32,530 (30,185 - 35,022)	2011	Modelled	IHME
31,333 (29,056 - 33,738)	2010	Modelled	IHME
30,611 (28,418 - 33,016)	2009	Modelled	IHME
29,671 (27,590 - 31,990)	2008	Modelled	IHME
28,701 (26,694 - 30,881)	2007	Modelled	IHME
27,985 (26,076 - 30,138)	2006	Modelled	IHME
27,242 (25,403 - 29,330)	2005	Modelled	IHME
26,287 (24,541 - 28,240)	2004	Modelled	IHME
26,004 (24,309 - 27,918)	2003	Modelled	IHME
25,293 (23,674 - 27,122)	2002	Modelled	IHME
24,439 (22,913 - 26,212)	2001	Modelled	IHME
23,578 (22,096 - 25,300)	2000	Modelled	IHME
22,700 (21,193 - 24,409)	1999	Modelled	IHME
21,850 (20,334 - 23,461)	1998	Modelled	IHME
21,121 (19,696 - 22,687)	1997	Modelled	IHME
20,584 (19,155 - 22,118)	1996	Modelled	IHME
20,201 (18,781 - 21,711)	1995	Modelled	IHME
19,577 (18,175 - 21,045)	1994	Modelled	IHME
18,940 (17,555 - 20,435)	1993	Modelled	IHME
18,010 (16,624 - 19,510)	1992	Modelled	IHME
17,433 (16,011 - 19,047)	1991	Modelled	IHME
16,950 (15,387 - 18,693)	1990	Modelled	IHME
21,698	2016	Modelled	WHO

Showing out of

Technical notes

Percent of liver cancer deaths attributable to HCV

National

Download

Value (%)	Year	Type	Source
39 (35 - 43)	2019	Modelled	IHME
39 (35 - 43)	2018	Modelled	IHME
39 (35 - 43)	2017	Modelled	IHME
40 (36 - 44)	2016	Modelled	IHME
41 (37 - 44)	2015	Modelled	IHME
41 (37 - 44)	2014	Modelled	IHME
41 (37 - 44)	2013	Modelled	IHME
41 (37 - 44)	2012	Modelled	IHME
40 (37 - 44)	2011	Modelled	IHME
40 (37 - 44)	2010	Modelled	IHME
40 (37 - 43)	2009	Modelled	IHME
40 (37 - 43)	2008	Modelled	IHME
40 (37 - 43)	2007	Modelled	IHME
40 (37 - 42)	2006	Modelled	IHME
39 (36 - 42)	2005	Modelled	IHME
39 (36 - 42)	2004	Modelled	IHME
39 (36 - 42)	2003	Modelled	IHME
39 (36 - 42)	2002	Modelled	IHME
39 (36 - 42)	2001	Modelled	IHME
39 (36 - 42)	2000	Modelled	IHME
39 (36 - 42)	1999	Modelled	IHME
39 (36 - 42)	1998	Modelled	IHME
39 (36 - 42)	1997	Modelled	IHME
39 (36 - 42)	1996	Modelled	IHME
39 (35 - 42)	1995	Modelled	IHME
38 (35 - 42)	1994	Modelled	IHME
38 (35 - 42)	1993	Modelled	IHME
38 (35 - 41)	1992	Modelled	IHME
38 (35 - 41)	1991	Modelled	IHME
38 (34 - 41)	1990	Modelled	IHME

Showing out of

Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)

Download

Value	Year	Type	Source
30 (11 - 49)	2016	Survey/reported	NASEN, 2015; Wejnert C et al, 2016; Des Jarlais D et al , 2013

Technical notes

HBV National Action Plan

Source:

HBV elimination goal

Source:

HBV testing policy

Pregnant women, Risk-based

Source:

HepB birth dose policy

Yes

Source: WHO

Year of birth dose introduction

1999

Source: WHO

Eligible for HBV generic medicines

Source: MPP

HCV National Action Plan

Source:

HCV elimination goal

Source:

HCV testing policy

Universal

Source:

Eligible for HCV generic medicines

Source: MPP

At least one needle-syringe exchange program (NSP) operational

Yes

Source: Harm Reduction International

At least one opioid substitution therapy (OST) program operational

Yes

Source: Harm Reduction International

NSP in at least one prison

Source: Harm Reduction International

OST in at least one prison

Yes

Source: Harm Reduction International

% of substance use disorder facilities offering hepatitis testing

Many (31-60%)

Source: WHO

Overview

HBV elimination goal

HCV elimination goal

Prevalence (national)

Modelled

Survey/surveillance

Roberts H et al, 2016

Hofmeister MG et al, 2019 (Adjusted)

Hepatitis related deaths (national)

Modelled

Survey/surveillance

No data available

HBV chart

Modelled

Survey/surveillance

No data available

HCV chart

Prevalence < 5

HBV

0.03 (%)

2019, latest modelled

(0.02 - 0.04(%))

IHME

Prevalence PWID

HCV

53.10 (%)

2016, latest modelled

(38.10 - 68(%))

Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

No. of syringes/PWID/year

Survey/surveillance

HCV

2016

(11 - 49)

NASEN, 2015; Wejnert C et al, 2016; Des Jarlais D et al , 2013

Eligible for HBV generic medicines

Eligible for HCV generic medicines

Latest news

HHS Releases its First Viral Hepatitis Elimination Plan in the United States

21 Jan 2021

View all

Action plan

The United States National Viral Hepatitis Action Plan 2017-2020

2017

Office of HIV/AIDS and Infectious Disease Policy (OHAIDP)

View all

Elimination champion

Dr. Lesley Miller

Dr. Miller built a program in an urban hospital setting treating 500 patients annually with a cure rate of 98%.

News

Pan American Health Organization and Task Force for Global Health Join Forces on Disease Elimination

22 Oct 2020

"Innovations in Hepatitis Elimination" Author Interview: October 13th 11 AM ET

30 Sep 2020

CGHE Community of Practice Newsletter: August 2020

02 Sep 2020

"Innovations in Hepatitis Elimination": 2nd Author Interview on Sept 10th 11-11:30 AM ET

28 Aug 2020

Blog: Key Takeaways from the Interim Report Card on Progress towards Global Hepatitis Elimination

28 Jul 2020

Launch of new series "Innovations in Hepatitis Elimination": Register now for first author interview July 22nd

14 Jul 2020

Petition to Continue United States Support for the World Health Organization to Detect Emerging Infections and Eliminate Viral Hepatitis, HIV, TB, Neglected Tropical Diseases and Other Global Health Threats

30 Jun 2020

Blog: Local Champions Team Up to Make HCV Micro-Elimination Possible in Georgia

25 Jun 2020

Announcing the 1st Annual Hepatitis Elimination Video Contest Results

29 Apr 2020

Action plans

The United States National Viral Hepatitis Action Plan 2017-2020

2017

Office of HIV/AIDS and Infectious Disease Policy (OHAIDP)

New York State Viral Hepatitis Strategic Plan 2016—2020- United States

2016

New York State Department of Health (NYSDOH)

California Viral Hepatitis Prevention Strategic Plan, 2016-2020: A Report of the California Viral Hepatitis Coordinating Committee and the California Department of Public Health-- United States

2018

California Viral Hepatitis Coordinating Committee and the California Department of Public Health

Maryland Hepatitis C Prevention and Control Plan 2002-- United States

2002

Maryland Department of Health and Mental Hygiene

A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults

2006

Mast, E. E.,Weinbaum, C. M.,Fiore, A. E.,Alter, M. J.,Bell, B. P.,Finelli, L.,Rodewald, L. E.,Douglas, J. M., Jr.,Janssen, R. S.,Ward, J. W., Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

Hep C Free Washington: Plan to Eliminate Hepatitis C in Washington State by 2030-- United States

2019

Hep C Free Washington

California Adult Viral Hepatitis Prevention Strategic Plan, 2010-2014

2010

California Adult Viral Hepatitis Prevention Coordinating Committee and State of California California Department of Public Health Center for Infectious Diseases